Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: A retrospective survey of more than 9000 German patients with MS

European Journal of Neurology

Volumn 18, Issue 8, 2011, Pages 1036-1045

  Maurer M ^a   Dachsel, R ^b   Domke, S ^b   Ries, S ^c   Reifschneider, G ^c   Friedrich, A ^d   Knorn, P ^d   Landefeld, H ^d   Niemczyk, G ^e   Schicklmaier, P ^e   Wernsdorfer C ^e   Windhagen, S ^f   Albrecht, H ^g   Schwab, S ^h  

^a CARITAS KRANKENHAUS   (Germany)

^b MS Schwerpunktpraxis Dachsel/Domke   (Germany)

^c Neurocenter Odenwald   (Germany)

^d Zentrum für ambulante Neurologie   (Germany)

^e Biogen GmbH   (Germany)

^f Department of Neurology   (Germany)

^g Neurozentrum Riem   (Germany)

^h UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Disease activity; Immunomodulatory treatment; Magnetic resonance imaging; Relapsing remitting multiple sclerosis

Indexed keywords

BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL DECISION MAKING; COHORT ANALYSIS; DISEASE COURSE; FEMALE; GERMANY; HEALTH SURVEY; HUMAN; IMAGE ENHANCEMENT; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; FEMALE; GERMANY; HEALTH CARE SURVEYS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79960320673     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03313.x     Document Type: Article

References (18)

1. Linker R, Gold R. Behandlung der multiplen Sklerose. Psychopharmakotherapie 2007; 14: 209-214.
2. Multiple Sclerosis Therapy Consensus Group (MSTCG). Escalating immunomodulatory therapy of multiple sclerosis - current therapeutic recommendations. J Neurol 2008; 255: 1449-1463.
3. Freitag P, Kappos L, Radü EW. Stellenwert der Magnetresonanztomographie bei Diagnose und Krankheitsmonitoring der Multiplen Sklerose. Schweiz Arch Neurol Psychiatr 2000; 151: 47-56.
4. O'Rourke K, Walch C, Antonello G, Hutchinson M. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 336-342.
5. Twork S, Nippert I, Scherer P, Haas J, Pöhlau D, Kugler J. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr Med Res Opin 2007; 23: 1209-1215.
6. Waubant EL. (accessed 03/23/2010).
7. Coyle P, Arnason B, Hurwitz B, Lublin F. Optimising outcomes in multiple sclerosis: a consensus initiative. Mult Scler 2009; 15(Suppl. 2): S5-S35.
8. Durelli L, Barbero P, Bergui M, et al. MRI activity and neutralising antibody as predictors of response to interferon β treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79: 646-651.
9. Limmroth V, Malessa R, Zettl UK, et al. Quality assessment in multiple sclerosis therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol 2007; 254: 67-77.
10. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
11. Herz J, Zipp F, Siffrin V. Neurodegeneration in autoimmune CNS inflammation. Exp Neurol 2009; 225: 9-17.
12. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
13. Rudick R, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
14. Tomassini V, Paolillo A, Giugni E, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287-293.
15. Chiu AW, Richert N, Ehrmantraut M, et al. Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol 2009; 66: 39-43.
16. Giacomini PS, Arnold DL, Bar-Or A, Antel JP. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much? Arch Neurol 2009; 66: 19-20.
17. Association of British Neurologists (ABN). (accessed 03/23/2010).
18. National Multiple Sclerosis Association (NMSA). (accessed 03/23/2010).